CD8A and ovarian carcinoma: Prior studies have demonstrated a prognostic role of CD8+ cells in patients with ovarian cancer.19–22 Immunohistochemical analyses of tumor samples of patients in the mITT analysis set revealed an imbalance in the density of tumor CD8+ cells, which was much lower in Group A than in Groups B and C. The different immunological malignant tissue profiles may translate into worse disease outcomes in Group A than Group B. DC-based immunotherapy as monotherapy generally fails to sufficiently reverse tumor progression, leading to the development of combination regimens.